Ramón González Manzano

Ramón González Manzano

Specialty: Medical oncology
Specialty: Medical Oncology
Hospitals where he/she works:
  • Hospital Quirónsalud Torrevieja
Serving specialties:
  • Medical Oncology

He is currently responsible for the Genetic Counsel Unit of the Oncology Platform of the Hospital Quirónsalud Torrevieja. One of its main occupations is the development of clinical applications of Cancer Genomics. Since mid-2010, he has promoted and carried out the application of the expression microarray technique in the prediction of the efficacy of antineoplastic agents in cancer patients. It is also preparing a project for the application in oncology of the new generation sequencing technologies.

Dr. González Manzano, completed his specialization in Medical Oncology (via MIR) in 1993 at the University Clinic of Navarra in Pamplona, ​​and in 1994 he obtained a Doctorate in Medicine from the Faculty of Medicine of the University of Navarra. He worked as an assistant doctor of Oncology at the Marqués de Valdecilla Hospital in Santander in 1993 (between April and September). In 1995 he began his training as a biologist and molecular geneticist at the MRC Center in Cambridge (United Kingdom). In October of 1997 and until September of 2001 he carried out a second postdoc in the Molecular Mechanisms Laboratory of the Department Cell and Cancer Biology of the National Cancer Institute in Rockville, Maryland (USA). In October of 2001 and until May of 2003 he was a research collaborator of the Division of Oncology of the Foundation for Applied Medical Research (FIMA) of the University of Navarra in Pamplona. In August 2003, he worked as a medical oncologist at the Hospital S. Jaime until January 2004. Afterwards, he made some brief stays in international laboratories (in Europe and in the USA).

Since October 2006, he has been part of the Genetic Counseling Unit of the Oncology Platform of the USP Hospital S. Jaime de Torrevieja (Alicante), where besides the tasks of the Unit, he is also in charge of the development and application of recent advances from molecular biology to the diagnosis and treatment of cancer patients treated in the Oncology Platform in close collaboration with the Dept. of Pathological Anatomy.

Specialities that it attends:

Oncology

Information and medical appointment

Plataforma de Oncología: (+34) 966 925 733

(+34) 966 921 313 / (+34) 966 925 761

ACADEMIC TRAINING:

- Bachelor of Medicine, University of Navarra, 1987.
- Medical Specialist in Medical Oncology, University Clinic of Navarra, 1993.
- Doctor of Medicine, Faculty of Medicine, University of Navarra, 1994.

SCIENTIFIC PUBLICATIONS:

- Manzano Ramon G., Luis Montuenga, Mark Dayton, Paul Dent, Ichiro Kinoshita, Silvestre Cambra, PhuongMai Nguyen, Yung-Hyun Choi, Jane Trepel, Nelly Auersperg, and Michael Birrer. CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene 2002; 21 (28): 4435-47.

- Kinoshita I., Leaner V., Katabami D.T., Manzano R.G., Sabichi A., Birrer M.J. Identification of cJun-responsive genes in Rat-1a cells using multiple techniques: increased expression of stathmin is necessary for cJun-mediated anchorage-independent growth. Oncogene 2003; 22 (18): 2710-22.

- Vicent S, López-Picazo JM, Toledo G, Lozano MD, Torre W, García-Corchón C, Quero C, Soria J-C, Martín-Algarra S, Manzano RG and Montuenga LM. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer 2004; 90: 1047-1052.
Vicent S., Garayoa M., Lopez-Picazo J.M., Lozano M.D, Toledo G, Thunissen F, Manzano RG, Montuenga LM. Mitogen-Activated Protein Kinase Phosphatase-1 (CL100/MKP-1) is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res 2004; 10(11): 3639-3649.

- Gonzalez,Manzano R.; Martinez,Navarro E.; Eugenieva,E.; Fernandez Morejon,F.J.; Farre,J.; Brugarolas,A. A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib. Clin Trans Oncol 2008; 10: 442-444.